tezacitabine and edotecarin

Physicians and patients alike have been heartened by the recent advances in the treatment of colorectal cancer. The emergence of novel agents that are active in the treatment of this devastating disease, such as cetuximab and bevacizumab, has been particularly notable. However, even before these recent events, a substantial change in prognosis for patients with metastatic colorectal cancer had occurred as a result of advances in traditional chemotherapeutic agents. Refinements in dose, schedule, and sequence continue to be made that could lead to further improvements in outcomes. Additionally, new chemotherapeutic agents with promise for activity in colorectal cancer are being studied. Chemotherapy is likely to remain a central element of the treatment strategy. Our understanding of its current role is discussed in this article.

Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Epothilones; Fluorouracil; Glutamates; Guanine; Humans; Indoles; Organoplatinum Compounds; Oxaliplatin; Pemetrexed